What Families Should Know Before Pediatric Bone Marrow Transplantation
Pediatric bone marrow transplantation — also called stem cell transplantation or haematopoietic cell transplantation (HCT) — is one of the most intensive treatments in childhood cancer and blood disorder care. For families facing this decision, understanding what the process involves, what donor options exist, and what risks and timelines to expect can make the experience significantly less overwhelming. This guide is written specifically for parents and caregivers.
Five things families most need to understand before transplant
- Transplant replaces your child's blood-forming system with a donor's — it is a treatment for the underlying disease, not just a blood transfusion.
- There are several donor types. Not having a fully matched sibling does not mean transplant is impossible — haploidentical (parent) and unrelated donor transplants are well-established.
- The conditioning phase (before transplant) involves high-dose chemotherapy, sometimes with radiation, which destroys the existing marrow. This is one of the hardest parts of the process.
- Graft-versus-host disease (GvHD) is the most important transplant-specific complication to understand. Prevention and management of GvHD are central to transplant care.
- Recovery is measured in months to years, not weeks. Preparation for the long post-transplant period — not just the transplant itself — is essential.
What Is a Pediatric Bone Marrow Transplant?
A bone marrow transplant replaces a child's blood-forming stem cells — the cells in the bone marrow that produce all blood cells — with healthy stem cells from a donor. Before the donor cells can be infused, the child's existing bone marrow is destroyed using high-dose chemotherapy (and sometimes radiation), a phase called conditioning. The donor cells are then given through an intravenous line, similar to a blood transfusion. Over the following weeks, the donor cells travel to the bone marrow and begin producing new blood cells — a process called engraftment.
The terms "bone marrow transplant," "stem cell transplant," and "haematopoietic cell transplant (HCT)" all refer to the same overall procedure. The main difference is where the stem cells come from:
Transplant is used when a child's disease — most commonly leukaemia, aplastic anaemia, thalassaemia, or certain immune disorders — cannot be cured by chemotherapy alone, or when relapse has occurred and the best chance of long-term remission requires replacing the blood-forming system entirely.
Understanding Donor Types: You Have More Options Than You May Think
One of the most common fears families have is: "What if we can't find a donor?" Understanding the range of donor options — and how they compare — is important context before making a transplant decision.
Matched sibling donor (MSD)
A brother or sister who is a full HLA match (typically 10/10 antigens matched). Historically considered the ideal donor. However, due to smaller family sizes in many countries and the rising prevalence of genetic screening, matched siblings are available for fewer than 30% of paediatric transplant candidates in China — and the proportion is declining.
Matched unrelated donor (MUD)
A donor found through a bone marrow registry (such as China's CMDP — the Chinese Marrow Donor Program) who is not related to the child but is closely HLA-matched. Registry searching takes time — typically weeks to months — and may not be successful for children from certain ethnic backgrounds with less representation in registries.
Haploidentical donor — usually a parentMost common in China
A half-matched donor — typically a parent (who is by definition 50% HLA-matched to their child) or a sibling. Haploidentical transplant has become the dominant donor type in China's paediatric transplant landscape, accounting for over 56% of all cases in the national registry. Chinese haematology centres have developed and refined specific protocols — including combined graft strategies using peripheral blood plus bone marrow or cord blood, and T-cell manipulation — to manage the greater immunological challenge of a half-matched donor.
For international families without a matched sibling or a registry match, haploidentical transplant using a parent donor is an established, well-documented option. Read more about haploidentical transplant options in China.
Cord blood
Stem cells from donated umbilical cord blood, stored in cord blood banks. Does not require a perfect HLA match. Particularly useful for certain metabolic diseases (e.g. mucopolysaccharidoses) where cord blood may offer specific biological advantages. Less commonly used as the sole graft source for leukaemia in larger children due to limited cell numbers.
The Transplant Timeline: What Families Should Expect
Understanding the transplant timeline helps families plan and avoids the shock of a process that is longer and more demanding than many expect.
Pre-transplant workup (2–6 weeks)
- Disease restaging — confirming the child is in the best disease state possible before transplant
- Organ function assessment (heart, lungs, kidneys, liver) to confirm fitness for conditioning
- Donor evaluation and stem cell collection planning
- Central venous line (Hickman line or PICC) placement for medication delivery
- Family counselling and consent process
Conditioning (7–14 days)
- High-dose chemotherapy (and sometimes radiation) to destroy the child's existing bone marrow
- This is typically the hardest phase — nausea, fatigue, mouth sores, and infection risk are common
- The child is in hospital throughout; close monitoring and supportive care are essential
Transplant day — Day 0
- Donor cells are infused through the central line, like a blood transfusion
- The procedure itself is often surprisingly straightforward — the challenge is what comes before and after
Engraftment period (Days +7 to +30)
- The donated cells travel to the bone marrow and begin producing blood cells
- The child has virtually no immune system during this period — infection risk is highest
- Engraftment is confirmed when blood counts begin to recover (usually around Day +14 to +21)
- GvHD may begin to appear in this phase
Early recovery and outpatient monitoring (Month 1–6)
- If no major complications, children are typically discharged 4–8 weeks after transplant
- Frequent outpatient visits continue — often multiple times per week initially
- GvHD monitoring, infection prophylaxis, and immunosuppression management are central
- Families must remain near the transplant centre during this period
Long-term recovery (Months 6–24+)
- Gradual reduction in medications as immune reconstitution progresses
- Re-vaccination schedule (the child's immune system does not remember prior vaccines)
- Monitoring for late effects of conditioning and chronic GvHD
- School and normal activity return depends on individual recovery
Key Risks Families Need to Understand
Transplant carries significant risks. Families should understand these risks honestly — not to be frightened away from transplant, but so they can have informed discussions with the medical team and prepare appropriately.
Graft-versus-host disease (GvHD)
GvHD occurs when donor immune cells treat the child's body as foreign and attack it. This is the most transplant-specific complication to understand.
Preventing and managing GvHD is one of the most active areas of research and clinical focus in transplant medicine. Haploidentical transplants require specific GvHD prevention strategies — an area where Chinese transplant centres have developed and published significant experience.
Serious infection
During and after conditioning, the child has essentially no immune system. Bacterial, viral, and fungal infections are major risks during the engraftment window and the months that follow. Strict infection control — protective isolation, prophylactic anti-infective medications, and careful monitoring — is the standard approach at experienced transplant centres.
Graft failure
In a small proportion of cases, donor cells fail to engraft — either because the immune system rejects them (primary graft failure) or because engraftment initially succeeds but then fails later (secondary graft failure). Graft failure is more common with cord blood and certain haploidentical protocols, and is one reason combined graft strategies have been developed.
Disease relapse after transplant
Transplant does not guarantee the underlying disease will not return. Relapse after transplant is among the most difficult clinical situations in paediatric haematology, and options in this setting — donor lymphocyte infusion, CAR-T therapy, or second transplant — depend heavily on the specific case. This is why disease status at the time of transplant matters so much.
Facing a transplant decision and want a structured expert review?
An online MDT consultation with a specialist paediatric transplant team can review your child's records, confirm whether transplant is the most appropriate next step, clarify donor options, and outline what Chinese centres can offer — without requiring you to travel first.
Request a paediatric case reviewQuestions Families Should Ask Before Agreeing to Transplant
Transplant teams work through these questions routinely, but families have every right to ask them explicitly and receive clear answers:
Why is transplant recommended now, rather than more chemotherapy?
Understanding whether transplant is the only path to cure, or one of several options, is important for informed decision-making.
What is my child's disease status going into transplant?
Transplant outcomes are significantly better when a child is in remission. If not in remission, ask whether additional treatment before transplant should be considered.
What donor type is being recommended, and why?
The choice between MSD, MUD, haploidentical, and cord blood involves trade-offs in GvHD risk, engraftment speed, and availability. Families should understand the reasoning.
What conditioning regimen will be used, and what are the short- and long-term side effects?
Myeloablative versus reduced-intensity conditioning affects both the intensity of the experience and the long-term risks, including effects on fertility and organ function.
How many transplants of this type — same disease, same donor type — has this centre performed?
Centre experience matters. High-volume centres with published outcomes data in the specific indication and donor type provide more reliable basis for expectations.
What is the plan if transplant does not work, or if disease comes back?
Understanding the post-transplant safety net — including CAR-T access, DLI, or second transplant protocols — before committing is reasonable and important.
Practical Preparation for Families — Including International Caregivers
Transplant is a marathon, not a sprint. Families who are practically prepared before admission tend to manage the process better than those who arrive without plans in place.
Why Some International Families Consider China for Paediatric Transplant
China's paediatric transplant programme has grown rapidly and now operates at a scale that is globally significant. The 2017–2024 CCBMTR national registry recorded 22,381 paediatric transplants across 51 dedicated centres — more than 4,000 per year, with sustained growth. Specific reasons international families seek case review or treatment in China include:
- Donor shortage: no matched sibling or registry match available in the home country — Chinese centres have extensive experience with haploidentical (parent donor) transplant
- Indication-specific experience: aplastic anaemia, thalassaemia major, and certain rare blood disorders where Chinese centres have large published cohorts
- Protocol access: specific conditioning regimens and combined graft strategies developed and refined in China
- Second opinion: families who want expert review of a transplant recommendation before committing — particularly for complex cases or when disease status is uncertain
This page is part of ChinaMed Waypoint's paediatric leukemia and blood disorders resources for international families navigating transplant decisions.
Supportive Care During and After Transplant in China
Supportive care — managing the physical and emotional side effects of transplant — is a central component of care at major Chinese paediatric transplant centres. In addition to standard medical supportive care (antiemetics, pain management, nutritional support), integrative approaches may be offered alongside transplant medicine at some centres:
- Nutritional support teams specialising in transplant-related appetite loss and mucositis
- Acupuncture for nausea and fatigue management during and after conditioning — used as a complementary approach alongside standard antiemetic medication
- Psychological support services for children and caregivers throughout the transplant period
- Paediatric rehabilitation support for children recovering from prolonged hospitalisation
All supportive approaches are used alongside — not instead of — the transplant protocol. Any integrative approach should be discussed with and coordinated by the transplant team.
Related Guides
What 22,381 Pediatric Transplants Reveal About HCT Practice in China
CCBMTR nationwide registry data on 22,381 pediatric transplants in China — haploidentical donors now at 56%, PBSC at 89%.
Haploidentical Transplant in China: When There Is No Matched Donor
How haploidentical (half-matched) transplant works, who can donate, and what Chinese centres have published on outcomes.
How Supportive Care Helps During Cancer Treatment
What supportive care looks like for children during and after transplant — including integrative approaches available in China.
Frequently Asked Questions
What is the difference between a bone marrow transplant and a stem cell transplant?
These terms refer to the same overall procedure — replacing a child's blood-forming cells with healthy cells from a donor. The difference lies in where the donor cells are collected from. "Bone marrow transplant" traditionally refers to cells harvested directly from the donor's bone marrow. "Stem cell transplant" or "peripheral blood stem cell transplant" refers to cells collected from the donor's bloodstream after medication is used to mobilise them out of the marrow. In China, peripheral blood stem cells (PBSC) are now used in approximately 89% of paediatric transplants, though the procedures are often still collectively called bone marrow transplant in everyday language.
Can a parent be the donor for their child's bone marrow transplant?
Yes. Parents are by definition half-matched (haploidentical) donors — sharing 50% of HLA antigens with their child. Haploidentical transplant using a parent donor has become the most common donor type in paediatric transplantation in China, accounting for over 56% of all cases in the CCBMTR 2017–2024 registry. Chinese haematology centres have accumulated substantial published experience with this approach, and outcomes in appropriately selected cases are comparable to matched donor transplants for many indications.
How long does recovery after paediatric bone marrow transplant take?
The immediate inpatient period is typically 4–8 weeks, covering the conditioning phase, transplant day, and the engraftment window. After discharge, close outpatient monitoring continues for at least 3–6 months. Full immune reconstitution — the point at which a child's immune system is functioning independently — takes 1–2 years. Children with complications such as chronic graft-versus-host disease may require longer monitoring and treatment. School return and resumption of normal activities depends on the individual child's recovery trajectory.
What is graft-versus-host disease (GvHD) and how serious is it?
Graft-versus-host disease (GvHD) occurs when the donor's immune cells recognise the recipient's body as foreign and mount an immune response against it. Acute GvHD typically occurs within the first 100 days and may affect the skin, gut, or liver. Chronic GvHD can develop later and affect multiple organ systems. Severity ranges from mild (manageable with medication) to severe (life-threatening). GvHD prevention is a central part of transplant protocols, and GvHD management is one of the areas of active clinical focus at specialist transplant centres. Haploidentical transplants carry a different GvHD risk profile compared to matched transplants, which is why combined graft strategies and T-cell depletion approaches are used.
When should families consider seeking a second opinion before proceeding with transplant?
A second opinion before transplant is reasonable in several situations: when families want to confirm that transplant is the most appropriate treatment for their child's specific disease and stage; when there is no matched donor and the haploidentical approach is being recommended; when a previous transplant has failed and a second transplant is being considered; or when families are uncertain about protocol choice, timing, or the centre's experience with the specific indication. An online MDT consultation with a specialist paediatric transplant team does not require travel and can help clarify these questions before any decision is made.
Medical disclaimer
ChinaMed Waypoint is a coordination service, not a medical provider. Nothing in this article constitutes medical advice. All treatment decisions — including the decision to proceed with transplantation, donor selection, and protocol choice — should be made in consultation with a qualified paediatric haematologist or transplant physician who has reviewed the child's complete clinical records.
Request a structured paediatric transplant case review
If your family is facing a bone marrow transplant decision — whether to confirm the recommendation, explore donor options, or understand what Chinese centres can offer — an online MDT consultation is a practical first step that requires no travel commitment.
Request a case reviewWe coordinate with specialist paediatric haematology and transplant teams in China.